Brighten Optix Corporation

TWO:6747 Taiwan Medical Devices
Market Cap
$163.60 Million
NT$5.41 Billion TWD
Market Cap Rank
#19645 Global
#980 in Taiwan
Share Price
NT$199.00
Change (1 day)
+0.00%
52-Week Range
NT$129.00 - NT$199.00
All Time High
NT$413.99
About

Brighten Optix Corporation researches, develops, manufactures, and sells contact lenses in Taiwan and internationally. The company offers orthokeratology, a non-invasive and reversible method of vision correction by using a hard contact lens to alter the shape of the front surface of the cornea; gas permeable lenses for single vison, multifocal, and irregular cornea and keratoconus correction, un… Read more

Brighten Optix Corporation (6747) - Net Assets

Latest net assets as of September 2025: NT$1.16 Billion TWD

Based on the latest financial reports, Brighten Optix Corporation (6747) has net assets worth NT$1.16 Billion TWD as of September 2025.

Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (NT$1.49 Billion) and total liabilities (NT$331.68 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.

Key Net Assets Metrics

Metric Value
Current Net Assets NT$1.16 Billion
% of Total Assets 77.72%
Annual Growth Rate 22.08%
5-Year Change 94.26%
10-Year Change N/A
Growth Volatility 24.63

Brighten Optix Corporation - Net Assets Trend (2017–2024)

This chart illustrates how Brighten Optix Corporation's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.

Annual Net Assets for Brighten Optix Corporation (2017–2024)

The table below shows the annual net assets of Brighten Optix Corporation from 2017 to 2024.

Year Net Assets Change
2024-12-31 NT$1.41 Billion +10.65%
2023-12-31 NT$1.28 Billion +2.99%
2022-12-31 NT$1.24 Billion +4.64%
2021-12-31 NT$1.19 Billion +62.90%
2020-12-31 NT$728.17 Million +2.87%
2019-12-31 NT$707.86 Million +59.86%
2018-12-31 NT$442.81 Million +26.51%
2017-12-31 NT$350.02 Million --

Equity Component Analysis

This analysis shows how different components contribute to Brighten Optix Corporation's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

  • Retained earnings have grown by 190.8% over the analyzed period, indicating profitable operations and earnings retention.

Current Equity Component Breakdown (December 2024)

Component Amount Percentage
Retained Earnings NT$532.95 Million 37.76%
Other Components NT$878.43 Million 62.24%
Total Equity NT$1.41 Billion 100.00%

Brighten Optix Corporation Competitors by Market Cap

The table below lists competitors of Brighten Optix Corporation ranked by their market capitalization.

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Brighten Optix Corporation's equity between the two most recent reporting periods.

Equity Growth Insights

  • From 2023 to 2024, total equity changed from 1,273,107,000 to 1,411,381,000, a change of 138,274,000 (10.9%).
  • Net income of 149,793,000 contributed positively to equity growth.
  • Dividend payments of 130,000,000 reduced retained earnings.
  • Other factors increased equity by 118,481,000.

Equity Change Factors (2023 to 2024)

Factor Impact Contribution
Net Income NT$149.79 Million +10.61%
Dividends Paid NT$130.00 Million -9.21%
Other Changes NT$118.48 Million +8.39%
Total Change NT$- 10.86%

Book Value vs Market Value Analysis

This analysis compares Brighten Optix Corporation's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

  • Current price-to-book ratio: 3.84x
  • The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
  • The price-to-book ratio has decreased from 12.51x to 3.84x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date Book Value per Share Market Price P/B Ratio
2017-12-31 NT$15.91 NT$199.00 x
2018-12-31 NT$20.08 NT$199.00 x
2019-12-31 NT$32.09 NT$199.00 x
2020-12-31 NT$32.87 NT$199.00 x
2021-12-31 NT$49.01 NT$199.00 x
2022-12-31 NT$50.93 NT$199.00 x
2023-12-31 NT$52.46 NT$199.00 x
2024-12-31 NT$51.89 NT$199.00 x

Capital Efficiency Dashboard

This dashboard shows how efficiently Brighten Optix Corporation utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

  • Current Return on Equity (ROE): 10.61%
  • The company shows good efficiency in utilizing shareholder equity.
  • DuPont Analysis Breakdown:
  • • Net Profit Margin: 19.53%
  • • Asset Turnover: 0.48x
  • • Equity Multiplier: 1.13x
  • Recent ROE (10.61%) is below the historical average (16.76%), suggesting potential challenges in capital efficiency.

Historical Capital Efficiency Metrics

Year Return on Equity Net Profit Margin Asset Turnover Equity Multiplier Economic Value Added
2017 16.59% 17.85% 0.50x 1.85x NT$23.08 Million
2018 16.66% 18.27% 0.65x 1.41x NT$29.40 Million
2019 16.33% 23.61% 0.58x 1.20x NT$44.69 Million
2020 17.23% 23.11% 0.62x 1.20x NT$52.47 Million
2021 20.36% 37.41% 0.47x 1.16x NT$122.75 Million
2022 20.65% 34.33% 0.52x 1.16x NT$131.80 Million
2023 15.65% 26.66% 0.50x 1.16x NT$71.93 Million
2024 10.61% 19.53% 0.48x 1.13x NT$8.65 Million

Industry Comparison

This section compares Brighten Optix Corporation's net assets metrics with peer companies in the Medical Devices industry.

Industry Context

  • Industry: Medical Devices
  • Average net assets among peers: $1,274,214,400
  • Average return on equity (ROE) among peers: 6.56%

Peer Company Comparison

Company Net Assets Return on Equity Debt-to-Equity Market Cap
Brighten Optix Corporation (6747) NT$1.16 Billion 16.59% 0.29x $71.13 Million
Health & Life Co., Ltd. (1781) $372.58 Million -4.71% 1.15x $12.97 Million
Hi-Clearance (1788) $3.00 Billion 11.98% 0.65x $104.25 Million
Radiant Innovation (3373) $865.89 Million -3.30% 0.08x $18.65 Million
Wellell Inc (4106) $1.31 Billion 13.81% 0.24x $37.12 Million
Rossmax International Ltd (4121) $1.33 Billion 1.93% 1.30x $38.32 Million
United Orthopedic (4129) $1.77 Billion 7.55% 0.46x $300.33 Million
Dynamic Medical Technologies (4138) $1.76 Billion 11.67% 0.71x $39.41 Million
Ok Biotech Co Ltd (4155) $1.30 Billion 9.66% 0.71x $44.61 Million
Bioptik Technology (4161) $717.83 Million 6.76% 1.11x $30.42 Million
EPS Bio Technology Corp. (4183) $309.15 Million 10.25% 0.77x $4.27 Million